Starfire Investment Advisers Inc. reduced its stake in shares of Pfizer, Inc. (NYSE:PFE) by 4.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,604 shares of the biopharmaceutical company’s stock after selling 900 shares during the quarter. Starfire Investment Advisers Inc.’s holdings in Pfizer were worth $725,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Rehmann Capital Advisory Group boosted its stake in Pfizer by 5.6% in the first quarter. Rehmann Capital Advisory Group now owns 120,374 shares of the biopharmaceutical company’s stock valued at $4,118,000 after buying an additional 6,343 shares in the last quarter. IFC Holdings Incorporated FL boosted its stake in Pfizer by 5.5% in the first quarter. IFC Holdings Incorporated FL now owns 71,424 shares of the biopharmaceutical company’s stock valued at $2,449,000 after buying an additional 3,697 shares in the last quarter. Foster & Motley Inc. boosted its stake in Pfizer by 3.3% in the first quarter. Foster & Motley Inc. now owns 298,763 shares of the biopharmaceutical company’s stock valued at $10,221,000 after buying an additional 9,501 shares in the last quarter. Harwood Advisory Group LLC boosted its stake in Pfizer by 29.3% in the first quarter. Harwood Advisory Group LLC now owns 13,256 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 3,005 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its stake in Pfizer by 1.7% in the first quarter. Fisher Asset Management LLC now owns 32,759,530 shares of the biopharmaceutical company’s stock valued at $1,120,704,000 after buying an additional 554,777 shares in the last quarter. 69.36% of the stock is currently owned by institutional investors.
In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the sale, the insider now directly owns 74,506 shares in the company, valued at $2,436,346.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now owns 132,124 shares of the company’s stock, valued at $4,492,216. The disclosure for this sale can be found here. Over the last quarter, insiders sold 374,621 shares of company stock valued at $12,796,098. 0.06% of the stock is currently owned by corporate insiders.
Several analysts recently weighed in on PFE shares. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Monday, July 17th. BMO Capital Markets raised Pfizer from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $33.00 to $37.00 in a research note on Wednesday, August 2nd. UBS AG reissued a “buy” rating and set a $38.00 price target on shares of Pfizer in a research note on Monday, July 31st. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Finally, Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company. Pfizer presently has an average rating of “Hold” and a consensus target price of $38.48.
Shares of Pfizer, Inc. (PFE) opened at $35.30 on Tuesday. The firm has a market capitalization of $209,697.67, a P/E ratio of 14.07, a price-to-earnings-growth ratio of 2.49 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer, Inc. has a 1-year low of $30.51 and a 1-year high of $36.78.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the company posted $0.61 earnings per share. equities analysts anticipate that Pfizer, Inc. will post 2.59 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be issued a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.63%. Pfizer’s payout ratio is currently 79.01%.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/14/starfire-investment-advisers-inc-has-725000-stake-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.